Anzeige
Mehr »
Lynx Broker
Login
Montag, 14.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 852738 ISIN: BE0003739530 Ticker-Symbol: UNC 
Tradegate
14.10.19
08:06 Uhr
66,64 Euro
+0,16
+0,24 %
Branche
Pharma
Aktienmarkt
EURONEXT-100
BEL-20
1-Jahres-Chart
UCB SA Chart 1 Jahr
5-Tage-Chart
UCB SA 5-Tage-Chart
RealtimeGeldBriefZeit
66,56
66,66
09:53
66,64
66,66
09:52

Aktuelle News zur UCB Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrBelgium's UCB to buy Ra Pharmaceuticals for $ 2.1bn3
Börsennews zur UCB Aktie und weiteren Hot Stocks erhalten
FrUCB to acquire Ra Pharmaceuticals: Belgium-based drugmaker UCB has agreed to pay $2.1 billion ...2
DoUCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma-
DoRa Pharmaceuticals News: RARX Stock Flies 100% on $2.1 Billion UCB Deal2
DoRa Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB4
DoEuroBiotech Report-UCB inks $2.5B deal; Oxford spinout; Bayer, Merck and Gilead16
DoThe Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO8
DoUCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris7
DoUCB gets bigger in rare diseases with $2.1bn purchase of Ra Pharma5
DoBelgium's UCB to acquire Ra Pharma in cash deal valued at about $2.5 billion5
DoUCB agrees to buy Ra Pharma for $2.5B3
DoBelgium's UCB to buy US-based Ra Pharmaceuticals for $2.1bn3
DoUCB to expand rare disease offerings with Ra Pharma: Belgium biopharmaceutical group UCB has reached an agreement to acquire ...1
DoUCB bags a rival to Soliris in $2.1B buyout deal - but will an increasingly vigilant FTC sign off?-
DoUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases291- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside...
► Artikel lesen
DoUCB to acquire Ra Pharmaceuticals in $2.1 billion deal1
DoUCB Agrees to Buy Ra Pharmaceuticals for About $2.5 Billion2
DoUPDATE 1-Belgium's UCB to buy Ra Pharmaceuticals in $2.1 billion cash deal3
DoUCB Agrees To Buy Ra Pharma In $2.1 Bln Deal2
DoBelgium's UCB to buy Ra Pharmaceuticals for $2.1 billion6
Seite:  Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1